Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
المؤلفون المشاركون
Zhang, Qing
Zhang, Haixu
Ding, Jiage
Liu, Hongyan
Li, Huizhong
Li, Hailong
Lu, Mengmeng
Miao, Yangna
Li, Liantao
Zheng, Junnian
المصدر
Journal of Immunology Research
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-10-15
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Adoptive chimeric antigen receptor-modified T or NK cells (CAR-T or CAR-NK) offer new options for cancer treatment.
CAR-T therapy has achieved encouraging breakthroughs in the treatment of hematological malignancies.
However, their therapeutic efficacy against solid tumors is limited.
New regimens, including combinations with chemical drugs, need to be studied to enhance the therapeutic efficacy of CAR-T or NK cells for solid tumors.
An epithelial cell adhesion molecule- (EpCAM-) specific second-generation CAR was constructed and transduced into NK-92 cells by lentiviral vectors.
Immune effects, including cytokine release and cytotoxicity of the CAR-NK-92 cells against EpCAM-positive colon cancer cells, were evaluated in vitro.
Synergistic effects of regorafenib and CAR-NK-92 cells were analyzed in a mouse model with human colorectal cancer xenografts.
The CAR-NK-92 cells can specifically recognize EpCAM-positive colorectal cancer cells and release cytokines, including IFN-γ, perforin, and granzyme B, and show specific cytotoxicity in vitro.
The growth suppression efficacy of combination therapy with regorafenib and CAR-NK-92 cells on established EpCAM-positive tumor xenografts was more significant than that of monotherapy with CAR-NK-92 cells or regorafenib.
Our results provided a novel strategy to treat colorectal cancer and enhance the therapeutic efficacy of CAR-modified immune effector cells for solid tumors.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Zhang, Qing& Zhang, Haixu& Ding, Jiage& Liu, Hongyan& Li, Huizhong& Li, Hailong…[et al.]. 2018. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1192296
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Zhang, Qing…[et al.]. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. Journal of Immunology Research No. 2018 (2018), pp.1-11.
https://search.emarefa.net/detail/BIM-1192296
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Zhang, Qing& Zhang, Haixu& Ding, Jiage& Liu, Hongyan& Li, Huizhong& Li, Hailong…[et al.]. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1192296
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1192296
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر